Compliance updated on Sep 10, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Embecta Corp.

EMBC ✗ NOT COMPLIANTFree checks used up today ☆ Track — members

NASDAQ · Healthcare · Medical Equipment, Supplies & Distribution ·

USA Small Cap Analyst: HOLD

Last Close

$5.30

▲ +0.19%

Market Cap $300.30M · Vol 296.77K

Price charts are for members

Interactive price history from intraday to 5 years, on every stock and ETF.

See plans

Key Metrics

P/E Ratio

3.58

FWD: 3.00

Market Cap

$300.30M

Small Cap

Div Yield

0.76%

Quarterly dividend

EPS Growth

-37.76%

YoY

RSI (14)

53.51

Momentum

Beta

0.84

vs Market

52W High

$14.91

65.13% below

52W Low

$2.77

90.97% above

Volume

296.77K

Avg 577.42K

P/B

N/A

Price-to-book

ROE

N/A

Return on equity

Free Float

97.99%

Public shares

Shariah Compliance8 STANDARDS

✗ Embecta Corp. (EMBC) stock is currently not Shariah compliant

You’ve used your 10 free compliance checks today

Choose a plan

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See which standards it fails, the exact ratios behind the verdict, and halal alternatives.Members see the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does EMBC pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+1.15%

+1.34%

+70.42%

-40.38%

YTD

-55.39%

-63.04%

-65.76%

N/A

Financials & Valuation

TTM · Annual

Total Revenue	$1.08B
Net Income	$95.40M
Revenue Growth (YoY)	-8.05%
Gross Margin	62.89%
Operating Margin	30.48%
Net Profit Margin	8.83%
ROE	N/A
ROA · ROIC	11.47% · 20.67%

P/E Ratio	3.58
Forward P/E (FY1)	3.00
PEG Ratio	0.42
P/S	0.77
P/B	N/A
P/FCF	4.56
EPS Growth	-37.76%
Outstanding Shares	56.66M

Technical Indicators

50-Day SMA	$4.51
200-Day SMA	$7.29
RSI (14)	53.51
Beta	0.84
52-Week High	$14.91
52-Week Low	$2.77

Volume Today	296.77K
Avg Daily Volume (30D)	577.42K
Relative Volume	0.51x
Volatility (10D)	60.69
Volatility (30D)	65.78
Free Float	97.99%

Analyst Consensus

HOLD

Current Price $5.30

Mean Target $10.00

52W Low$2.77 52W High$14.91

Current

Target

$2.77 $14.91

Current Analyst target

+88.68% upside potential · 4 analysts

Identifiers

ExchangeNASDAQ

FIGIBBG014L7D4H0

ISINUS29082K1051

CountryUSA

Sub-IndustryMedical Equipment, Supplies & Distribution (NEC)

Earnings DateNov 23, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

ABT Abbott Laboratories +0.36% MDT Medtronic PLC -0.41% COR Cencora, Inc. +2.50% BDX Becton Dickinson and Co -0.13% 7741.T HOYA CORPORATION -0.22%

Company Profile

Embecta Corp. is a global medical device company. It provides solutions to improve the health and well-being of people living with diabetes. Its portfolio of marketed products, including a variety of pen needles, syringes and safety injection devices. Its pen needles are sterile, single-use, medical devices, designed to be used in conjunction with pen injectors that inject insulin or other diabetes medications. It sells safety pen needles, which have shields on both ends of the cannula that automatically deploy after the injection to help prevent needlestick exposure and injury during injection and disposal. Its traditional and safety pen needles are compatible and frequently used with pen injectors in the market. It sells sterile, single-use insulin syringes, which are used to inject insulin drawn from insulin vials. It distributes its products through channels, including retail, hospitals and pharmacies. It is also a manufacturer of medical devices and drug delivery technologies.